Preclinical science regarding cannabinoids as analgesics: An overview

Pain Research and Management

Volumn 10, Issue SUPPL. A, 2005, Pages

  Lynch, Mary E ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Cannabinoid opioid interactions; Cannabinoid receptors; Cannabinoids; Chronic pain; Endocannabinoids

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANALGESIC AGENT; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; NABILONE; PALMIDROL; RIMONABANT; VIRODHAMINE;

ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; BIOSYNTHESIS; CENTRAL NERVOUS SYSTEM; HUMAN; HYPOTHALAMUS; NOCICEPTION; NONHUMAN; PAIN; REVIEW; SIGNAL TRANSDUCTION; VISCERAL PAIN;

EID: 33645729615     PISSN: 12036765     EISSN: None     Source Type: Journal    
DOI: 10.1155/2005/169093     Document Type: Review

References (80)

1. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-7.
2. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001;63:569-611.
3. Martin BR, Lichtman AH. Cannabinoid transmission and pain perception. Neurobiol Dis 1998;5:447-61.
4. Richardson JD. Cannabinoids modulate pain by multiple mechanisms of action. J Pain 2000;1:2-14.
5. Walker JM, Strangman NM, Huang SM. Cannabinoids and pain. Pain Res Manag 2001;6:74-9.
6. Rice AS. Cannabinoids and pain. Curr Opin Investig Drugs 2001;2:399-414.
7. Rice AS, Farquhar-Smith WP, Nagy I. Endocannabinoids and pain: Spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 2002;66:243-56.
8. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-13.
9. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4.
10. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5.
11. Sim LJ, Selley DE, Xiau R, Childers SR. Differences in G-protein activation by mu- and delta-opioid, and cannabinoid, receptors in rat striatum. Eur J Pharmacol 1996;307:97-105.
12. Herkenham M, Lynn AB, Johnson MR, Melvin LS, De Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci 1991;11:563-83.
13. Mailleux P, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 1992;48:655-68.
14. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical localization of cannabinoid CB1 receptors in rat central nervous system. Neuroscience 1998;83:393-411.
15. Herkenham M. Localization of cannabinoid receptors in brain and periphery. In: Pertwee RG, ed. Cannabinoid Receptors. New York: Academic Press 1995:145-66.
16. Hohmann AG, Tsou K, Walker JM. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN 55,212-2. Neurosci Lett 1998;257:119-22.
17. Hohmann AG, Briley EM, Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res 1999;822:17-25.
18. Hohmann AG, Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 1999;92:1171-5.
19. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997;74:129-80.
20. Sanudo-Pena MC, Tsou K, Delay ER, Hohmann AG, Force M, Walker JM. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci Lett 1997;223:125-8.
21. Wenger T, Fernandez-Ruis JJ, Ramos JA. Immunohistochemical demonstration of CB1 cannabinoid receptors in the anterior lobe of the pituitary gland. J Neuroendocrinol 1999;11:873-8.
22. Klein TW. Cannabis and immunity. In: The Health Effects of Cannabis. Kalant H, Corregal W, eds. Toronto: Centre for Addiction and Mental Health, 1999:349-73.
23. Klein TW. Cannabinoids and the immune system. Pain Res Manage 2001;6:95-101.
24. Gong JP, Onaivi E, Uhl G. Cannabinoid CB2 receptors: Immunhistochemical localization in rat brain. ICRS abstracts. 15th Annual Symposium on the Cannabinoids, Clearwater, Florida, June 24-27, 2005.
25. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-9.
26. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83-90.
27. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995;215:89-97.
28. DePetrocellis L, Cascio MG, DiMarzo V. The endocannabinoid system: A general view and latest additions. Br J Pharmacol 2004;141:765-74.
29. Bisogno T, Melck D, Bobrov MY, et al. N-acyl-dopamines: Novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 2000;351:817-24.
30. Huang SM, Bisogno T, Trevisani M, et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid receptors. Proc Natl Acad Sci 2002;99:8400-5.
31. Porter AC, Sauer JM, Knierman MD, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002;301:1020-4.
32. Mukhopadhyay S, Shim JY, Assi AA, Norford D, Howlett AC. CB(1) cannabinoid receptor-G-protein association: A possible mechanism for differential signaling. Chem Phys Lipids 2002;121:91-109.
33. DiMarzo V, Bifulco M, DePetrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004;3:771-84.
34. Lichtman AH, Martin BR. The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced nociception in rats. Pharmacol Biochem Behav 1997;57:7-12.
35. Howlett AC. Pharmacology of cannabinoid receptors. Ann Rev Pharmacol Toxicol 1995;35:607-34.
36. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002;296:678-82.
37. Martin WJ, Lai NK, Patrick SL, Tsou K, Walker JM. Antinociceptive actions of WIN 55,212-2 following intraventricular administration in rats. Brain Res 1993;629:300-4.
38. Martin WJ, Patrick SL, Coffin PO, Tsou K, Walker JM. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci 1995;56:2103-10.
39. Martin WJ, Tsou K, Walker JM. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci Lett 1998;232:33-6.
40. Martin WJ, Coffin PO, Attias E, Balinsky M, Tsou K, Walker JM. Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res 1999;822:237-42.
41. Meng ID, Manning BH, Martin WJ, Fields HL. An analgesia circuit activated by cannabinoids. Nature 1998;395:381-3.
42. Meng ID, Johansen JP. Antinociception and modulation of rostral ventromedial medulla neuronal activity by local microinfusion of a cannabinoid receptor agonist. Neuroscience 2004;124:685-93.
43. Yaksh TL. The antinociceptive effects of intrathecally administered levonantradol and desacetyllevonantradol in the rat. J Clin Pharmacol 1981;21:334S-40S.
44. Welch SP, Stevens DL. Antinociceptive activity of intrathecally administered cannabinoids alone and in combination with morphine in mice. J Pharmacol Exp Ther 1992;262:10-8.
45. Lichtman AH, Martin BR. Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther 1991;258:517-23.
46. Lichtman AH, Martin BR. Cannabinoid-induced antinociception is mediated by a spinal alpha 2-noradrenergic mechanism. Brain Res 1991;559:309-14.
47. Richardson JD, Aanonsen L, Hargreaves KM. SR141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 1997;319:R3-4.
48. Richardson JD, Aanonsen L, Hargreaves KM. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 1998;345:145-53.
49. Richardson JD, Aanonsen L, Hargreaves KM. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci 1998;18:451-7.
50. Calignano A, la Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998;394:277-81.
51. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998;75:111-9.
52. Malan TP, Ibrahim MM, Deng H, et al. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001;93:239-45.
53. Dogrul A, Husamettin G, Akar A, Yildiz O, Bilgin F, Guzeldemir E. Topical cannabinoid antinociception: Synergy with spinal sites. Pain 2003;105:11-6.
54. Yesilyurt O, Dogrul A, Gul H, et al. Topical cannabinoid enhances topical morphine antinociception. Pain 2003;105:303-8.
55. Strangman NM, Patrick SL, Hohmann AG, Tsou K, Walker JM. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Res 1998;813:323-8.
56. Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Nat Acad Sci (USA) 1999;96:198-203.
57. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004;74:1317-24.
58. Smith PB, Welch SP, Martin BR. Interactions between delta-9- tetrahydrocannabinol and kappa opioids in mice. J Pharmacol Exp Ther 1994;268:1381-7.
59. Dixon WE. The pharmacology of cannabis. Indica Br Med J 1899;2:1354-7.
60. Tsou K, Lowitz KA, Hohmann AG, et al. Suppression of noxious stimulus-evoked expression of fos-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience 1995;70:791-8.
61. Herzberg U, Eliav E, Bennett GJ, Kopin IJ. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 1997;221:157-60.
62. Hohmann AG, Martin WJ, Tsou K, Walker JM. Inhibition of noxious stimulus evoked activity of the spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sci 1995;56:2111-9.
63. Hohmann AG, Herkenham M. Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal cord following neonatal capsaicin treatment. Neurosci Lett 1998;252:13-6.
64. Martin WJ, Hohman AG, Walker JM. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by the cannabinoid WIN 55,212-2: Correlation between electrophysiological and antinociceptive effects. J Neurosci 1996;16:6601-11.
65. Strangman NM, Walker JM. The cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J Neurophysiol 1999;82:472-7.
66. Lim G, Sung B, Ji RR, Mao J. Upregulation of spinal cannabinoid-1- receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 2003;105:275-83.
67. Costa B, Colleoni M, Conti S, et al. Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. Br J Pharmacol 2004;141:4-8.
68. Burstein SH, Audettte CA, Breuer A, et al. Synthetic nonpsychotropic cannabinoids with potent anti-inflammatory, analgesic, and leukocyte antiadhesion activities. J Med Chem 1992;35:3135-41.
69. Burstein SH, Stebulis JA, Torres R, et al. Ajulemic acid, a non-psychoactive cannabinoid acid, downregulates activation of human synovial cells. ICRS 2004, abstract 209.
70. Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Fledmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum 2004;50:985-98.
71. Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannnabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134:845-52.
72. Sawynok J. Topical and peripherally acting analgesics. Pharm Rev 2003;55:1-20.
73. Klein TW, Lane B, Newton CA, Friedman H. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 2000;225:1-8.
74. Hohmann AG, Farthing JN, Zvonok AM, Makriyannis A. Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther 2004;308:446-53.
75. Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol 2002;135:181-7.
76. Rockwell C, Kaminski N. Anandamide metabolites from both cyclooxygenase enzymes cause inhibition of Il-2 secretion in murine splenocytes. ICRS 2004 Abstract 210.
77. Fowler CJ. Possible involvement of the endocannabinoid system in the actions of three clinically used drugs. Trends Pharmacol Sci 2004;25:59-61.
78. Hornby PJ, Prouty SM. Involvement of cannabinoid receptors in gut motility and visceral perception. Br J Pharmacol 2004;141:1335-45.
79. Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004;113:1202-9.
80. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999;58:315-48.